Nasdaq · Healthcare
Schrodinger, Inc. (SDGR)
As-reported financials and recent SEC filings for Schrodinger, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$255.9M
Net income
$-103.3M
Net margin
-40.4%
Diluted EPS
$-1.41
ROE
-28.4%
P/E (TTM)
—
Market cap
$1.26B
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $255.9M | $207.5M | $216.7M | $181.0M | $137.9M |
| Gross profit | $142.6M | $132.1M | $140.7M | $101.0M | $65.6M |
| Operating income | $-166.9M | $-209.3M | $-177.4M | $-146.8M | $-111.4M |
| Net income | $-103.3M | $-187.1M | $40.7M | $-149.2M | $-100.4M |
| Diluted EPS | $-1.41 | $-2.57 | $0.54 | $-2.10 | $-1.42 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-23
View on EDGAR →42026-06-23
View on EDGAR →42026-06-23
View on EDGAR →42026-06-23
View on EDGAR →42026-06-23
View on EDGAR →42026-06-23
View on EDGAR →42026-06-23
View on EDGAR →42026-06-23
View on EDGAR →Go deeper on SDGR
Search Schrodinger, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.